Ondamed Inc. announces the addition of Dr. Shari Lieberman to serve as the head of their research team. One of Dr. Lieberman's responsibilities is to document case studies for Ondamed Inc., including alleviation of plantar fasciitis (www.ondamed.net) using ONDAMED Biofeedback technology. Dr. Lieberman will facilitate studies examining the effects of ONDAMED on pain, sports medicine injuries, and other challenging conditions using the ONDAMED Biofeedback (www.ondamed.net) technology.
Dr. Lieberman holds a Master's degree in Nutrition, Food Science, and Dietetics from New York University and a Ph.D. in Clinical Nutrition and Exercise Physiology from the Union
Institute. She is a well-known clinician, researcher and author, appearing on numerous radio and television programs as an expert in the field of nutrition; She is the recipient of the
National Nutritional Foods Association 2003 Clinician of the Year Award and is the immediate past President of the American Association for Health Freedom. Dr. Lieberman is the Founding
Dean of New York Chiropractic College's Master of Science Program in Applied Clinical Nutrition.
Dr. Lieberman has documented numerous case studies for Ondamed Inc., compiling evidence of biofeedback in the alleviation of various conditions, including plantar fasciitis. Plantar
fasciitis is a common cause of heal pain in adults that can result in severe pain and decreased mobility. It is commonly treated with a combination of steroids, anti-inflammatory drugs,
and long-term physical therapy which appears to yield only temporary relief. Recent case studies documented with ONDAMED demonstrate the rapid and long lasting improvement clients have
seen after a small number of treatments.
The first case documented involved a 57-year-old female who had been diagnosed with plantar fasciitis in January of 2007. Numerous medical consultations led the patient through a series
of treatment approaches, including drug therapy, ultrasound therapy, and dietary and lifestyle changes. Although minor and temporary improvements were achieved, the patient experienced
severe side effects from the anti-inflammatory drugs that were administered and found that none of the treatments relieved the pain for more than short periods of time. She received her
first ONDAMED session in February of 2007, undergoing one session per week for three weeks. The ONDAMED technology is based on the principles of biophysics, using a broad range of pulsed
electromagnetic frequencies used to produce sound, causing a change in the patient's pulse at certain frequencies, and using this biofeedback information about the patient's response to
provide the identified frequencies in a biofeedback session. After only one ONDAMED session, she noticed immediate improvements in both her pain and pain-related depression. After
receiving a total of four more sessions over the next ten days, the patient saw tremendous improvements in mobility and continued reductions in pain and was able to walk normally for the
first time since developing plantar fasciitis. She is treated twice a week and has resumed her normal activities. With 2 ONDAMED sessions per week, she is currently able to lead a normal
life.
Similar success was achieved by an extremely overweight 55-year-old male patient who had also failed to achieve any long lasting pain management in his plantar fasciitis through three
weeks of treatment with the drug, Diclofenac. The patient, who was unable to put full weight on his left foot decided to try ONDAMED prior to receiving a steroid injection that was to be
his last resort. After just one session he experienced significant pain relief. Two weeks later he experienced a return of mild pain and received another treatment followed by 2
additional treatments. He has not experienced any return of the pain for more than 7 months. He is able to walk normally and resume his normal activities.
The New York-based company is excited to report the results of these case studies in the successful alleviation of plantar fasciitis pain. Dr. Lieberman is documenting a growing number of
patients experiencing significant relief using ONDAMED to improve a wide range of health issues. It is important to continue accumulating experiences to guide clinical research and new
uses.
ONDAMED is registered with the FDA as a Biofeedback device. It has also been approved by the AAABEM Institutional Review Board for testing as a secondary treatment device for various
disorders. The device has been used by hundreds of satisfied practitioners worldwide for the last 15 years with significant results in thousands of patients.
For more information on the ONDAMED Biofeedback System visit www.ondamed.net.
Contact: Ondamed Inc. 845-496-6673